Nothing Special   »   [go: up one dir, main page]

MXPA05011710A - Derivados de pirimidina con actividad de crf. - Google Patents

Derivados de pirimidina con actividad de crf.

Info

Publication number
MXPA05011710A
MXPA05011710A MXPA05011710A MXPA05011710A MXPA05011710A MX PA05011710 A MXPA05011710 A MX PA05011710A MX PA05011710 A MXPA05011710 A MX PA05011710A MX PA05011710 A MXPA05011710 A MX PA05011710A MX PA05011710 A MXPA05011710 A MX PA05011710A
Authority
MX
Mexico
Prior art keywords
pyrimidine derivatives
compounds
fused pyrimidine
crf
crf activity
Prior art date
Application number
MXPA05011710A
Other languages
English (en)
Inventor
Ryan Craig Schoenfeld
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MXPA05011710A publication Critical patent/MXPA05011710A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Esta invencion se relaciona con compuestos que en general son antagonistas del receptor CRF-1 y que se representan por la Formula I, en donde X1 es (CH2), n es 0 a 2 y R1, R2, R3 y R4 son como se definen en la especificacion; o isomeros individuales, mezclas racemicas o no racemicas de los isomeros o las sales farmaceuticamente aceptables de los mismos. La invencion se relaciona ademas con procesos para la preparacion de tales compuestos, con composiciones farmaceuticas que contienen estos compuestos y con metodos para su uso como agentes terapeuticos.
MXPA05011710A 2003-05-05 2004-04-27 Derivados de pirimidina con actividad de crf. MXPA05011710A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46887803P 2003-05-05 2003-05-05
PCT/EP2004/004411 WO2004099209A1 (en) 2003-05-05 2004-04-27 Fused pyrimidine derivatives with crf activity

Publications (1)

Publication Number Publication Date
MXPA05011710A true MXPA05011710A (es) 2006-01-23

Family

ID=33435209

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05011710A MXPA05011710A (es) 2003-05-05 2004-04-27 Derivados de pirimidina con actividad de crf.

Country Status (11)

Country Link
US (1) US7307082B2 (es)
EP (1) EP1622910A1 (es)
JP (1) JP2006525261A (es)
KR (1) KR100767272B1 (es)
CN (1) CN100372851C (es)
AU (1) AU2004235907B2 (es)
BR (1) BRPI0409986A (es)
CA (1) CA2523261C (es)
MX (1) MXPA05011710A (es)
RU (1) RU2328497C2 (es)
WO (1) WO2004099209A1 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
BRPI0507668A (pt) * 2004-02-14 2007-07-17 Irm Llc compostos e composições como inibidores de proteìna cinase
RU2006135120A (ru) * 2004-03-05 2008-04-10 Тайсо Фармасьютикал Ко. Производные пирролопиримидина
WO2006042102A2 (en) * 2004-10-05 2006-04-20 Neurogen Corporation Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds
MX2007005159A (es) 2004-10-29 2007-06-26 Tibotec Pharm Ltd Derivados de pirimidina biciclicos inhibidores del vih.
ES2348829T3 (es) 2006-03-31 2010-12-15 Janssen Pharmaceutica Nv Benzimidazol-2-il-pirimidinas y pirazinas moduladoras del receptor h4 de histamina.
BRPI0714908B8 (pt) * 2006-08-08 2021-05-25 Chugai Pharmaceutical Co Ltd derivados de pirimidina como inibidor de pi3k, composição farmacêutica e agente preventivo ou agente terapêutico de uma doença proliferativa que os compreende
ES2559319T3 (es) 2007-06-04 2016-02-11 Synergy Pharmaceuticals Inc. Agonistas de guanilato cliclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
JP2011522828A (ja) 2008-06-04 2011-08-04 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
SI2310012T1 (sl) * 2008-06-30 2015-06-30 Janssen Pharmaceutica N.V. Postopek za pripravo substituiranih pirimidinskih derivatov
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
DK2861595T5 (en) 2012-06-13 2018-01-15 Incyte Holdings Corp Substituted tricyclic compounds as FGFR inhibitors
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
ES2773543T3 (es) 2013-03-06 2020-07-13 Janssen Pharmaceutica Nv Benzoimidazol-2-ilpirimidinas moduladores del receptor de histamina H4
EP2968439A2 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
KR102269032B1 (ko) 2013-04-19 2021-06-24 인사이트 홀딩스 코포레이션 Fgfr 저해제로서 이환식 헤테로사이클
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
EA038045B1 (ru) 2015-02-20 2021-06-28 Инсайт Корпорейшн Бициклические гетероциклы в качестве ингибиторов fgfr
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
MX2020011718A (es) 2018-05-04 2021-02-15 Incyte Corp Formas solidas de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr) y procesos para prepararlas.
PE20210919A1 (es) 2018-05-04 2021-05-19 Incyte Corp Sales de un inhibidor de fgfr
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
JOP20220083A1 (ar) 2019-10-14 2023-01-30 Incyte Corp حلقات غير متجانسة ثنائية الحلقة كمثبطات لـ fgfr
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021113479A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
MX2022006691A (es) 2019-12-04 2022-09-19 Incyte Corp Derivados de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr).
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
EP4323405A1 (en) 2021-04-12 2024-02-21 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
JP2024522189A (ja) 2021-06-09 2024-06-11 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式ヘテロ環
CN114292274B (zh) * 2022-01-12 2023-12-19 中国药科大学 作为JAK激酶抑制剂的吡咯并[2,3-d]嘧啶类衍生物及制备方法和用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW530047B (en) * 1994-06-08 2003-05-01 Pfizer Corticotropin releasing factor antagonists
IL127873A0 (en) 1996-07-08 1999-10-28 Du Pont Pharm Co Amidinoindoles amidinoazoles and analogs thereof as inhibitors of factor xa and of thrombin
EP0964864B1 (en) 1997-02-05 2008-04-09 Warner-Lambert Company LLC Pyrido 2,3-d pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
US6432989B1 (en) * 1999-08-27 2002-08-13 Pfizer Inc Use of CRF antagonists to treat circadian rhythm disorders
WO2001055148A1 (en) 2000-01-27 2001-08-02 Warner-Lambert Company Pyridopyrimidinone derivatives for treatment of neurodegenerative disease
PT1333833E (pt) 2000-10-23 2011-12-09 Glaxosmithkline Llc Novo composto 8h-pirido[2,3-d]pirimidin-7-ona trissusbtituída para o tratamento de doenças mediadas por csbp/p38 cinase
EP1383747B1 (en) * 2001-04-30 2008-02-20 Glaxo Group Limited Fused pyrimidines as antagonists of the corticotropin releasing factor (crf)
US7462622B2 (en) * 2001-06-12 2008-12-09 Glaxo Group Limited Pyrrolo[2, 3-d] pyrimidine derivatives as corticotropin releasing factor antagonists

Also Published As

Publication number Publication date
US7307082B2 (en) 2007-12-11
CA2523261C (en) 2009-07-07
CA2523261A1 (en) 2004-11-18
CN1784409A (zh) 2006-06-07
JP2006525261A (ja) 2006-11-09
US20040224964A1 (en) 2004-11-11
EP1622910A1 (en) 2006-02-08
KR100767272B1 (ko) 2007-10-17
BRPI0409986A (pt) 2006-05-09
WO2004099209A1 (en) 2004-11-18
CN100372851C (zh) 2008-03-05
RU2328497C2 (ru) 2008-07-10
RU2005137825A (ru) 2006-08-10
AU2004235907B2 (en) 2007-08-30
AU2004235907A1 (en) 2004-11-18
KR20060004978A (ko) 2006-01-16

Similar Documents

Publication Publication Date Title
MXPA05011710A (es) Derivados de pirimidina con actividad de crf.
MXPA03011638A (es) Nuevos derivados de 4-piperazinil indol con afinidad por el receptor 5-ht6.
PL361361A1 (en) Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
EA200600811A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ТЕТРАГИДРОСПИРО {ПИПЕРИДИН-2,7'-ПИРРОЛО [3,2-b]ПИРИДИНА} И НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С 5-HT-РЕЦЕПТОРОМ
IL177291A0 (en) Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists
TW200517109A (en) Substituted pyridinones
EA200500342A1 (ru) Гетероциклические замещённые пиперазины для лечения шизофрении
TW200531694A (en) Acetylinic piperazine compounds and their use as metabotropic glutamate receptor antagonists
PL361282A1 (en) Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
HK1091200A1 (en) Arylindenopyridines and arylindenopyrimidines and their use as adenosine a2a receptor antagonists
NO20070837L (no) Pyrido-pyrido pyrimidinderivater, fremstilling derav samt terapeutisk anvendelse for behandling av cancer.
EA200501041A1 (ru) Замещенные производные 1-пиперидин-4-ил-4-пирролидин-3-илпиперазина и их применение в качестве антагонистов нейрокининов
PA8589601A1 (es) Derivados de indazol como antagonistas del crf
HUP0301272A2 (hu) 4-Fenil-piridin-származékok, mint neurokinin-1-receptor antagonisták, eljárás az előállításukra és alkalmazásuk gyógyszerkészítmények előállítására
YU53100A (sh) Derivati 2-ariletil-(piperidin-4-ilmetil)amina kao antagonisti muskarinskih receptora
NO20040589L (no) Arylsulfonylderivater med 5-HT6 reseptor affinitet.
DE602004005960D1 (de) Heteroaryl-substituierte pyrrolä2, 3- büpyridin-derivate als crf-rezeptor-antagonisten
MXPA04005426A (es) Derivados de pirazol de anillos fuisionados.
MXPA04005076A (es) Derivados de 4-piperidinil alquilamina como antagonistas del receptor muscarinico.
MXPA04005313A (es) Derivados de aminotetralin como antagonistas del receptor muscarinico.
MY140653A (en) Substituted diketopiperazines and their use as oxytocyn antagonists
NO20080671L (no) Bisykliske piperaziner som metabotrofiske glutamatreseptorantagonister
DK1537113T3 (da) Arylalkylindoler med serotoninreceptoraffinitet anvendelige som terapeutiske midler, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse
MXPA05011841A (es) Metil-indoles y metil-pirrolopiridinas como agonistas adrenergicos de alfa-1.
SE0301371D0 (sv) New Compounds

Legal Events

Date Code Title Description
FG Grant or registration